Barely Significant
← all excerpts

Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017-2018.

Vaccine X · 2023 · PMC9926188 · PMID 36798107

Europe PMCDOI
1
hedged sentence
0.0310
closest p · 0.6× alpha
0.0310
boldest claim

The sentences

marginally significantp = 0.031actually significant
The PPSV23 was associated with a marginally significant reduction risk of bacteremic pneumococcal pneumonia in the age subgroup >=60 years (HR: 0.74; 95% CI: 0.56–0.97; p = 0.031) and immunocompetent persons (HR: 0.72; 95% CI: 0.53–0.98; p = 0.035), but no benefits emerged against all pneumococcal pneumonia and/or all-cause pneumonia.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.